Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses.
It is becoming increasingly evident that the compartmentalization of immune responses is governed, in part, by tissue-selective homing instructions imprinted during T cell differentiation. In the context of allergic diseases, the fact that "disease" primarily manifests in particular tissue sites, despite pervasive allergen exposure, supports this notion. However, whether the original site of Ag exposure distinctly privileges memory Th2 immune-inflammatory responses to the same site, while sparing remote tissue compartments, remains to be fully investigated. We examined whether skin-targeted delivery of plasmid DNA encoding OVA via gene-gun technology in mice could generate allergic sensitization and give rise to Th2 effector responses in the skin as well as in the lung upon subsequent Ag encounter. Our data show that cutaneous Ag priming induced OVA-specific serum IgE and IgG1, robust Th2-cytokine production, and late-phase cutaneous responses and systemic anaphylactic shock upon skin and systemic Ag recall, respectively. However, repeated respiratory exposure to aerosolized OVA failed to instigate airway inflammatory responses in cutaneous Ag-primed mice, but not in mice initially sensitized to OVA via the respiratory mucosa. Importantly, these contrasting airway memory responses correlated with the occurrence of Th2 differentiation events at anatomically separate sites: indeed cutaneous Ag priming resulted in Ag-specific proliferative responses and Th2 differentiation in skin-, but not thoracic-, draining lymph nodes. These data indicate that Ag exposure to the skin leads to Th2 differentiation within skin-draining lymph nodes and subsequent Th2 immunity that is selectively manifested in the skin.
Alvarez
David
D
Division of Respiratory Diseases and Allergy, Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
Harder
Greg
G
Fattouh
Ramzi
R
Sun
Jiangfeng
J
Goncharova
Susanna
S
Stämpfli
Martin R
MR
Coyle
Anthony J
AJ
Bramson
Jonathan L
JL
Jordana
Manel
M
D000005:Abdomen; D000279:Administration, Cutaneous; D000336:Aerosols; D000818:Animals; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology*; D019470:Biolistics / Q000379:methods; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000473:pathology; D049109:Cell Proliferation; D004423:Ear; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology; D005260:Female; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007275:Injections, Intravenous; D008168:Lung / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D020545:Respiratory Mucosa / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D012867:Skin / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*
D000336:Aerosols; D000941:Antigens; D018984:Epitopes, T-Lymphocyte; D010047:Ovalbumin